Tissue Regenix Group PLC (LON:TRX)

Tissue Regenix Group PLC (LON:TRX)


Share Price
4.45 p
Change
0 (0.00 %)
Market Cap
£52.15 m
Proactive Investors - Run By Investors For Investors

Tissue Regenix Group PLC

TISSUE REGENIX GROUP is a pioneering, international medical technology company, focusing on the development of regenerative products utilising our two platform technologies, dCELL®, addressing soft tissue needs, and BioRinseTM, providing inductive bone allografts.

We are helping to transform the treatment of patients in three key areas: BioSurgery, Orthopaedics & Dental and Cardiac.

EPIC: TRX
Market: AIM:TRX
52-week High/Low: 10.70p / 3.10p
Sector: Pharma & Biotech
Market Cap: £52.15 m
Website: www.tissueregenix.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Tissue Regenix Group PLC


Tissue Regenix Group PLC Snapshot

Click here to read more information on our strategy.

BIOSURGERY

Click here for the overview

ORTHOPAEDICS

Click here for the overview

DENTAL

Click here for the overview

CARDIAC

Click here for the overview

Leeds and Texas.

The Board

John Samuel
Non-Executive Chairman

Steve Couldwell
Chief Executive Officer

Gareth Jones
Chief Financial Officer

Alan Miller
Non Executive-Director

Randeep Singh Grewal
Non Executive-Director

Jonathan Glenn
Non-Executive Director

Shervanthi Homer-Vanniasinkam
Non-Executive Director


 

Significant shareholders

As at 19 February 2019, shareholders holding more than 3% of the share capital of Tissue Regenix Group Plc are:

Name of Shareholder % of Voting Rights
Invesco Limited 28.74
Woodford Investment Management LLP 26.00
Techtran Group Limited 8.79
Baillie Gifford & Co Ltd 6.04
Jupiter Asset Management 5.88
Directors & Related Holdings 4.28
IP2IPO Limited 4.27

Shares not in public hands as at 19 February 2019 – 856,002,530 - 73%

Shares in issue as at 19 February 2019 - 1,171,730,823 ordinary shares of 0.5p each

The securities of Tissue Regenix Group plc are traded on the AIM market operated by the London Stock Exchange plc. Its shares have not been admitted, nor have any applications been made, for any of its shares to be admitted or traded on any other exchanges or trading platform.

Telephone
+44 (0)330 430 3052

Email
[email protected]

Fax
+44(0)190438517

Investor or Media Enquiries
Caitlin Pearson
Head of Communications
[email protected]

ADDRESS

UK OFFICE

Unit 1 & 2
Astley Way,
Swillington,
Leeds
LS26 8XT

US OFFICE
1808
Universal City Blvd,
Universal City,
Texas
78148

KEY ADVISORS

Nominated Advisor and Broker
STIFEL NICOLAUS EUROPE LIMITED

150 Cheapside,
London,
EC2V 6ET

Auditors
RSM

Central Square,
29 Wellington St,
Leeds
LS1 4DL

Solicitors
DLA PIPER UK LLP

Princes Exchange,
Princes Square,
Leeds,
LS1 4BY

Registrars
CAPITA

4 Beckenham Rd,
Beckenham,
Kent,
BR3 4TU

Columns Including TRX

VIEW ALL

Market Reports Including TRX

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use